From a total of 622 potential studies, six in vivo studies assessing the use of cannabinoids for treatment of melanoma were deemed eligible for the final analysis. The findings revealed cannabinoids, individually or combined, reduced tumor growth and promoted apoptosis and autophagy in melanoma cells.Out of the six papers on in vivo studies selected in this review, four of them demonstrated the beneficial effects of cannabinoids against melanoma. It is important to note in most of these studies, in vitro assays were initially carried out to validate that the selected treatments had reduced tumor-genesis and proliferation in melanoma cell lines.Simmerman et al. (2018) reported that the administration of cannabidiol repressed the tumor size significantly compared with the untreated group, while cisplatin demonstrated a greater reduction in tumor size but was associated with a lower quality of life.The THC/CBD combination (Sativex®) substantially promoted autophagy, apoptosis, and loss of viability in melanoma cells compared to a non-cannabinoid compound, temozolomide. Sometimes, a better treatment effect as a result of synergy was observed, with THC/CBD causing a substantial loss of melanoma viability compared to THC alone.